PrEP Access and Coverage Act of 2026
- Sponsor
- Sen. Smith, Tina [D-MN]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Mar 4, 2026
Bottom line
The bill aims to eliminate financial and administrative barriers to accessing HIV prevention medication and related services across all major health insurance programs and through public health initiatives.
What it actually does
This bill mandates comprehensive coverage for HIV prevention medication (PrEP and PEP) and related services across nearly all major health insurance programs, including private insurance, Medicare, Medicaid, CHIP, FEHBP, VA, TRICARE, and the Indian Health Service. It prohibits cost-sharing and preauthorization for these services, prevents discrimination by life, disability, and long-term care insurers against individuals taking PrEP, and establishes federal grant programs and public education campaigns to increase access and awareness.
Proponents argue
Supporters argue that increasing access to PrEP and PEP is a critical public health intervention that will significantly reduce new HIV transmissions, save lives, and ultimately lower healthcare costs associated with treating HIV. They emphasize the importance of addressing health disparities and ensuring equitable access to proven preventive care, particularly for communities disproportionately affected by HIV.
Opponents contend
Opponents, if any, might raise concerns about the increased costs for federal healthcare programs and private insurers due to mandated coverage and the elimination of cost-sharing. They could also argue about potential federal overreach into state-level healthcare decisions or the administrative burden placed on health plans and agencies.
The bill is 11 pages long and requires careful reading due to its numerous amendments to existing statutes across various healthcare programs.
Section 3(a)
Mandated Private Insurance Coverage for HIV Prevention Services
This provision amends the Public Health Service Act, ERISA, and the Internal Revenue Code to require private health insurance plans to cover FDA-approved HIV prevention drugs (PrEP/PEP), associated administrative fees, laboratory and other diagnostic procedures, and clinical follow-up and monitoring without any cost-sharing. It also prohibits plans from imposing preauthorization requirements for these services, unless a therapeutically equivalent drug is offered without such requirements.
Supporters argue
Supporters argue this provision is crucial for making HIV prevention accessible to all privately insured individuals, aligning with public health recommendations and reducing the overall burden of HIV by preventing new infections. They contend that eliminating cost-sharing and preauthorization removes significant barriers to uptake.
Critics contend
Critics may argue that mandating specific coverage and restricting utilization management tools like preauthorization could increase healthcare costs for private plans and employers, potentially leading to higher premiums for all policyholders. They might also raise concerns about federal interference in private insurance markets.
Tradeoffs
The provision balances the public health imperative of widespread HIV prevention with concerns about the financial impact on private insurance markets and the autonomy of health plans in managing benefits and costs.
Section 3(b)-(h)
Expanded Coverage and No Cost-Sharing Across Federal Health Programs
This section extends the mandate for comprehensive, cost-free coverage of HIV prevention services to a wide array of federal health programs. Specifically, it amends laws governing the Federal Employees Health Benefits Program (FEHBP), Medicaid, the Children's Health Insurance Program (CHIP), Medicare (Parts B and D), Department of Veterans Affairs (VA) healthcare, TRICARE for military beneficiaries, and the Indian Health Service (IHS). For each, it ensures that PrEP/PEP drugs, administrative fees, lab tests, and clinical monitoring are covered without cost-sharing or deductibles.
Section 4
Prohibition on Discrimination in Life, Disability, and Long-Term Care Insurance
This section makes it unlawful for life insurance, disability insurance, or long-term care insurance providers to deny coverage, limit coverage, increase premiums, or otherwise discriminate against an individual solely because they are taking medication for the purpose of preventing HIV acquisition (PrEP). It aims to protect individuals from being penalized for making proactive health choices.
Section 5
Public and Provider Education Campaigns
This section mandates the Secretary of Health and Human Services, through the CDC and other offices, to establish two education campaigns. The first is a public health campaign to educate the public on PrEP and PEP, counter stigma, and increase awareness in high-need communities. The second is a provider education campaign aimed at increasing awareness and readiness among healthcare professionals to offer PrEP and PEP, with a focus on cultural competency and addressing stigma.
Section 7
PrEP and PEP Grant Program
This section establishes a federal grant program, to be administered by the Secretary of Health and Human Services, for states, territories, Indian Tribes, and directly eligible entities. These grants are intended to support the establishment and operation of PrEP and PEP programs, specifically targeting uninsured and underinsured individuals and aiming to reduce disparities in access. Funds can be used for the drugs themselves, administrative fees, lab tests, clinical follow-up, outreach, education, and adherence services.
Section 9
Private Right of Action for Violations
This section grants any person aggrieved by a violation of this Act, or its amendments, the right to commence a civil action in an appropriate United States District Court or other court of competent jurisdiction. This action can be brought either individually or as a member of a class. If the plaintiff is the prevailing party, the court is mandated to order the defendant to pay the plaintiff's costs and reasonable attorney fees.
This clause specifies that for the purposes of this Act and any other provision of law, the current recommendations of the United States Preventive Service Task Force (USPSTF) regarding breast cancer screening, mammography, and prevention shall be considered the most current, *other than those issued in or around November 2009*.
Section 3(a)(1)(F)
Why it matters:This is likely a politically sensitive legislative maneuver to ensure certain breast cancer screening guidelines remain in effect for coverage purposes, overriding a specific past USPSTF recommendation (from November 2009) that may have been perceived as restrictive or controversial regarding the age and frequency of mammograms. Its placement might be to avoid a more direct and potentially contentious debate on USPSTF authority or specific screening guidelines.
Case for: Supporters would argue this ensures comprehensive breast cancer screening coverage, reflecting updated medical consensus or addressing public concerns about previous guidelines that may have limited access to mammography for certain age groups. It aims to prevent a specific, potentially unpopular, past recommendation from dictating current coverage.
Case against: Critics might contend that this provision interferes with the independent, evidence-based process of the USPSTF, potentially undermining its authority to issue clinical recommendations. They could also argue it is an unrelated 'rider' attached to an HIV prevention bill, diverting legislative focus.
Estimated impact: Potentially significant for women's health coverage, ensuring broader access to breast cancer screenings than the 2009 USPSTF guidelines might have allowed, impacting millions of individuals and health plans.
This section directs the Secretary of Health and Human Services to amend HIPAA regulations as necessary to ensure that individuals can access HIV prevention benefits (described in section 2713(a)(5) of the Public Health Service Act) under a family plan without any other individual enrolled in that family plan, including the primary subscriber or policyholder, being informed of such use of benefits.
Section 6
Why it matters:This is a crucial privacy protection designed to remove a significant barrier to care for individuals, particularly adolescents or young adults, who might fear family disclosure if they seek HIV prevention services. While not hidden in dense legal text, its importance might be underestimated if not explicitly highlighted, as it addresses a known practical challenge in accessing sensitive healthcare services.
Case for: Supporters argue this provision is essential for ensuring individuals, especially minors or young adults, feel safe and empowered to access PrEP without fear of family disclosure, which is a known barrier to care. This privacy protection can significantly increase PrEP uptake among populations where confidentiality is critical.
Case against: Some might argue that this provision could complicate family health plan administration or raise concerns about parental rights to information regarding their dependents' healthcare, though existing HIPAA rules already provide for individual privacy for certain sensitive services, even for minors.
Estimated impact: Significant for individual privacy and potentially increasing PrEP uptake among populations where family disclosure is a barrier, thereby contributing to public health goals.